Updates in Treatment Approaches for Prostate Cancer

Expert oncologists review recent updates in the treatment landscape of prostate cancer and consider how data will impact their own practice.

EP. 1: Overview of Metastatic HSPC: Diagnosis and Risk Stratification

June 26th 2023

Opening their first module on metastatic hormone-sensitive prostate cancer, panelists consider optimal diagnostic and risk stratification strategies for when a patient presents in clinic.

EP. 2: Systemic Treatment Armamentarium in Metastatic HSPC

June 26th 2023

Shared insight on the range of systemic therapy options available to patients who present with metastatic hormone-sensitive prostate cancer.

EP. 3: What is the Role of Locoregional Therapy in Metastatic HSPC?

July 25th 2023

Following their discussion on systemic therapy, expert panelists consider the value of locoregional therapy for a subset of patients with metastatic hormone-sensitive prostate cancer.

EP. 4: Informing Systemic Therapy Selection With Negative Data in HSPC

July 25th 2023

A brief conversation on negative clinical trial readouts and how they may help to inform optimal treatment pathways for patients with metastatic hormone-sensitive prostate cancer.

EP. 5: Evolving Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer

August 1st 2023

Comprehensive insight to key treatment modalities for patients with nonmetastatic castration-resistant prostate cancer and how to select amongst them.

EP. 6: Advent of PARP Inhibitors in Metastatic CRPC

August 1st 2023

Moving on to discuss metastatic castration-resistant prostate cancer, panelists highlight the evolving role of PARP inhibition in this setting.

EP. 7: Combination PARPi Strategies in Metastatic CRPC: Interpreting Data From Clinical Trials

August 8th 2023

Key opinion leaders in metastatic castration-resistant prostate cancer management review a subset of clinical trials focused on combination strategies with PARP inhibitors.

EP. 8: Radioligands in the Treatment of Metastatic CRPC: Lutetium-177–PSMA-617

August 8th 2023

Focused discussion on the role of lutetium-177–PSMA-617 as radioligand therapy in patients with metastatic castration-resistant prostate cancer.

EP. 9: Radioligands in the Treatment of Metastatic CRPC: Radium-223

August 15th 2023

Continuing their segment on radioligand therapy in metastatic castration-resistant prostate cancer, panelists highlight data behind use of radium-223.

EP. 10: Metastatic CRPC: Novel Treatment Strategies With Radioligand Therapy

August 15th 2023

Key opinion leaders share insight to novel combination strategies and clinical trials focused on radioligand therapy in metastatic castration-resistant prostate cancer.

EP. 11: Novel Therapeutic Targets in Metastatic CRPC

August 22nd 2023

A broad discussion on emerging therapeutic targets in metastatic castration-resistant prostate cancer and where they may fall within the treatment landscape.

EP. 12: Potential for CDK4/6 Inhibitors in Metastatic CRPC

August 22nd 2023

Expert panelists briefly reflect on clinical trial data with CDK4/6 inhibitors in metastatic castration-resistant prostate cancer and how their role in this setting might evolve.

EP. 13: Ongoing Clinical Trials in the Metastatic CRPC Setting

August 29th 2023

Key opinion leaders in metastatic castration-resistant prostate cancer share insight to key ongoing clinical trials within the landscape.

EP. 14: CAR T-Cell Therapy in Metastatic CRPC and Future Directions in Care

August 29th 2023

Closing out their final module, expert panelists consider the role of CAR T-cell therapy in metastatic castration-resistant prostate cancer and look toward future evolutions in the broader treatment landscape.